Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:41 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–22 of 22 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Hyperpolarized 129 Xenon Clear all

Conditions: Bronchiolitis Obliterans
Interventions: Hp 129Xenon; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 6 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Lungs; Developmental Disorder
Interventions: 129Xe; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Up to 6 Months
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Interventions: Hyperpolarized 129 Xenon Gas Comparing Progressive Pulmonary Fibrosis Treatment; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Cystic Fibrosis
Interventions: Initiation of CFTR Modulator, Hyperpolarized Xenon 129; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 6 Years to 21 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Pulmonary, Pneumonia, Hematopoietic System--Cancer
Interventions: 29-XeMRI imaging; Device
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Severe Asthma, COPD, Non-CF Bronchiectasis, Cystic Fibrosis (CF)
Interventions: Hyperpolarized 129 Xenon; Combination Product
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: E-Cig Use
Interventions: Hyperpolarized Xenon -129 MRI; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Respiratory Disorders
Interventions: Hyperpolarized 129 Xenon; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 6 Years and older
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2029
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Severe Asthma
Interventions: Hyperpolarized Xenon 129; Combination Product
Lead sponsor: Bastiaan Driehuys; Other
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: Hyperpolarized 129-Xenon gas, MRI; Drug · Device
Lead sponsor: Bastiaan Driehuys; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2020
U.S. locations: 2
States / cities: Durham, North Carolina • Madison, Wisconsin

Conditions: Lung Transplant Rejection
Interventions: Hyperpolarized 129-Xenon (MagniXene) MRI of the lung; Combination Product
Lead sponsor: Xemed LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Electronic Cigarette Related Lung Damage
Interventions: Hyperpolarized xenon 129, Cardiopulmonary Stress Test, Pulmonary Function Test, Chest CT; Drug · Diagnostic Test
Lead sponsor: Y. Michael Shim, MD; Other
Eligibility: 18 Years to 35 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2032
U.S. locations: 2
States / cities: Durham, North Carolina • Charlottesville, Virginia

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: Hyperpolarized 129 Xenon Gas Comparing Idiopathic Pulmonary Fibrosis (IPF) Treatment; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Respiratory Disorders
Interventions: Hyperpolarized 129 Xenon, MRI; Drug · Device
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2032
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: HSCT, Lung Transplant Recipient
Interventions: Hyperpolarized 129 Xenon; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Not listed
Enrollment: 550 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: HSCT, Respiratory, Gas Exchange Impairment
Interventions: Hyperpolarized 129 Xenon; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 3 Years and older
Enrollment: 550 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Bronchopulmonary Dysplasia
Interventions: MagniXene, hyperpolarized 129Xe MRI; Combination Product
Lead sponsor: Xemed LLC; Industry
Eligibility: Up to 1 Year
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Albuterol Sulfate, 2.5 Mg/3 mL (0.083%) Inhalation Solution, Vibrating Mesh Nebulizer, Metered Dose Inhaler, Jet Nebulizer; Drug · Device
Lead sponsor: Polarean, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Radiation Injury
Interventions: Hyperpolarized 129-Xenon gas, MRI; Drug · Device
Lead sponsor: Bastiaan Driehuys; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: ILD
Interventions: Xenon-129; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 18 Years to 90 Years
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Pulmonary Arterial Hypertension, Idiopathic Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension Associated With Connective Tissue Disease (Disorder), Connective Tissue Diseases
Interventions: 129Xe Hyperpolarized; Drug
Lead sponsor: Bastiaan Driehuys; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Pulmonary Hypertension, Pulmonary Arterial Hypertension
Interventions: 129Xe Hyperpolarized; Drug
Lead sponsor: Bastiaan Driehuys; Other
Eligibility: 18 Years to 75 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Durham, North Carolina

Search by objective public record fields.

Hp129 Xenon Imaging and BOS in Lung Transplantation

Use of Hyperpolarized 129Xe MR Lung Imaging in Infants

Xenon MRI and Progressive ILD

Non-contrast Lung Perfusion Mapping Applied for New Insights in Cystic Fibrosis

Hyperpolarized 129-Xenon Imaging in Adult Hematopoietic Cell Transplant Recipients With Pulmonary Impairment

Evaluation of Ventilation Defects Downstream of Mucus Plugs in Patients With Muco-Obstructive Lung Disease

Hyperpolarized Xenon-129 MR Imaging of the Lung

Use of Hyperpolarized Xenon Gas for Lung Imaging in Children and Adults

Downstream Effects of Airway Mucus Plugs on 129Xenon MRI in Severe Asthma

Using MRI to Visualize Regional Therapy Response in Idiopathic Pulmonary Fibrosis

Assessment of Chronic Lung Allograft Dysfunction Using Single-breath & Multi-breath Hyperpolarized Xenon-129 MRI

Dissolved Phase HXe-129 MRI: A Novel Biomarker to Quantify Pulmonary Pathology

Genentech Xenon MRI Idiopathic Pulmonary Fibrosis

Use of Hyperpolarized 129Xe MR Lung Imaging in Adults for Calibration

Technical Development of Xe MRI

Assessing Pulmonary Changes in HSCT

129Xe MRI in Pediatric Population With BPD

Comparison of Bronchodilator Response From Three Different Aerosol Delivery Methods in Patients With COPD Using Hyperpolarized Xe 129 MRI Ventilation Imaging

Longitudinal MR Imaging of Pulmonary Function in Patients Receiving Thoracic Radiation Treatment

Gas Exchange MRI to Visualize Regional Therapy Response in Interstitial Lung Disease

129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)

129 Xenon Imaging in Patients Treated With Sotatercept